Back to Results
First PageMeta Content
Antibody-drug conjugate / Immunology / Monoclonal antibodies / Immune system / Monomethyl auristatin E / Biotechnology / Targeted therapy / Maytansinoid / Bi-specific T-cell engager / Medicine / Pharmacology / Biology


Microsoft Word - ADC 2014 Report Jan 19, 2014
Add to Reading List

Document Date: 2014-01-23 03:32:35

Open Document

File Size: 140,67 KB

Share Result on Facebook

City

San Francisco / New Orleans / /

Company

Spirogen / Novartis / Lilly / Roche / Affinicon / GlaxoSmithKline / La Merie Publishing / Daiichi Sankyo / Endo Pharmaceuticals / Seattle Genetics / Heidelberg Pharma / Nerviano Medical Sciences / ImmunoGen / Astrazeneca / Bristol-Myers Squibb / /

Country

Germany / United States / /

Currency

USD / /

/

Event

Business Partnership / FDA Phase / M&A / /

Facility

Pipeline Analysis / ADC pipeline / Scripps Research Institute / /

IndustryTerm

site-specific conjugation technology / polymer technology / conjugation technology / technology providers / mere technology / technology outlicensing / biopharmaceutical / treatment of cancer / treatment for non-Hodgkin lymphoma / search item / conjugation systems / /

MedicalCondition

refractory multiple myeloma / solid tumors / epithelial ovarian cancer / LHRH receptor overexpressing tumors / cancers / tumor / cancer / /

Organization

German Ministry of Education / American Society of Hematology / Scripps Research Institute / /

Person

Serina Therapeutics Polyoxazoline / /

/

Position

Major / Representative / /

Product

dexamethasone / polyethylene glycol / CD70 / /

Technology

alpha / antibodies / polymerization / polymer technology / conjugation technology / pharmacokinetics / site-specific conjugation technology / ADC technology / ADC technologies / pharmacodynamics / /

URL

http /

SocialTag